Does PEGASPARGASE Cause Second primary malignancy? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Second primary malignancy have been filed in association with PEGASPARGASE (ONCASPAR). This represents 0.1% of all adverse event reports for PEGASPARGASE.
13
Reports of Second primary malignancy with PEGASPARGASE
0.1%
of all PEGASPARGASE reports
7
Deaths
10
Hospitalizations
How Dangerous Is Second primary malignancy From PEGASPARGASE?
Of the 13 reports, 7 (53.8%) resulted in death, 10 (76.9%) required hospitalization, and 4 (30.8%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEGASPARGASE. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does PEGASPARGASE Cause?
Febrile neutropenia (1,589)
Pyrexia (706)
Febrile bone marrow aplasia (668)
Sepsis (548)
Vomiting (530)
Neutropenia (521)
Abdominal pain (469)
Hypertriglyceridaemia (399)
Hypotension (388)
Thrombocytopenia (382)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which PEGASPARGASE Alternatives Have Lower Second primary malignancy Risk?
PEGASPARGASE vs PEGASYS
PEGASPARGASE vs PEGCETACOPLAN
PEGASPARGASE vs PEGFILGRASTIM
PEGASPARGASE vs PEGFILGRASTIM-APGF
PEGASPARGASE vs PEGFILGRASTIM-BMEZ